Methods related to TIM 3, a Th1-specific cell surface molecule, for activating antigen presenting cells

• US 8,697,069 B2
• Filed: 12/20/2011
• Issued: 04/15/2014
• Est. Priority Date: 01/30/2002
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated, Dana-Farber Cancer Institute
• Original Assignee: Brigham and Women's Hospital Incorporated, Dana-Farber Cancer Institute
• Inventors: Kuchroo, Vijay K., Monney, Laurent, Gaglia, Jason L., Greenfield, Edward A., Freeman, Gordon J., Waldner, Hanspeter
• Primary Examiner(s): Kim, Yunsoo
• Application Number:
  US13/331,387
• Publication Number:
  US 20120315286A1
• Time in Patent Office: 847 Days
• Field of Search: None
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/50 characterized by immunoglobulin fragments

Abstract

The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.

Claims

1. A method for promoting antigen presenting cell (APC) activation, comprising contacting a T cell with a T cell Immunoglobulin domain and Mucin domain (TIM-3)-binding molecule;

and contacting an APC with the T cell to activate the APC, wherein the TIM-3-binding molecule is an antibody specific for TIM-3 or an antigen-binding fragment of an antibody specific for TIM-3.

2. The method of claim 1, further comprising contacting the T cell with an antigen specifically bound by a T-cell antigen receptor of the T cell.

3. The method of claim 2, wherein the antigen is a cancer or tumor antigen.

4. The method of claim 1, wherein the APC is CD11b+.

5. The method of claim 1, wherein said APC activation comprises an increase in APC proliferation.

6. The method of claim 1, wherein said APC activation comprises an increase in Class II MHC expression by the APC.

7. The method of claim 1, further comprising measuring proliferative response of the contacted APC.

8. The method of claim 1, further comprising measuring expression of MHC Class II expression on the contacted APC.

9. The method of claim 1, wherein said contacting the APC with the T cell occurs ex vivo.

10. The method of claim 1, wherein said contacting the APC with the T cell occurs in vitro.

11. The method of claim 1, further comprising administering the activated APC to a subject in need thereof.